Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
Mazza S, Piazza O Sed N, Conforti FS, Fascì A, Rimondi A, Marinoni B, Casini V, Ricci C, Munari F, Pirola L, Invernizzi P, Girelli C, Lupinacci G, Pastorelli L, Cavallaro F, Ferraris L, Colucci A, Amato A, Eugenio Tontini G, Vecchi M, Fiorino G, Caprioli F.
Mazza S, et al. Among authors: munari f.
Clin Transl Sci. 2022 Jan;15(1):172-181. doi: 10.1111/cts.13131. Epub 2021 Sep 15.
Clin Transl Sci. 2022.
PMID: 34523800
Free PMC article.